Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyNeuro-OncologyVisceral SurgeryDiseaseBile Duct CarcinomaBreast CancerGastric CancerOvarian TumorPancreatic CancerPeritoneal Carcinomatosis, SecondaryTumor Biomarker DefinedSubgroupBRAF V600-MutationEpCAM positiveICD10C16.-C16.0C24.-C24.0C24.1C24.8C24.9C25.-C50.-C56C78.6MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, Ovarian EpithelialCommon Bile Duct NeoplasmsNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceAntineoplastic therapySubstanceCatumaxomabDabrafenibNaCl 0.9%TrametinibSubstanceCatumaxomabDabrafenibNaCl 0.9%TrametinibSubstanceCatumaxomabDabrafenibNaCl 0.9%TrametinibSubstanceCatumaxomabDabrafenibNaCl 0.9%TrametinibNo. Substances2 RadiotherapySupportive therapySubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolSubstanceGranisetronNaCl 0.9%ParacetamolNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHyponatremiaIncrease Alkaline PhosphataseIncrease AminotransferasesLymphopeniaNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorHeiss MMSalama AKSDiseaseLokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Peritonealkarzinose, sekundär, EpCAM positivOriginCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HProtocols in Revision 2 protocols foundCatumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)
